CD163 and classic Hodgkin lymphoma: From this point of view, not all macrophages may be “bad guys” [77]; the use of a single macrophage marker to stratify cHL patients may therefore be inappropriate; and a hypothetical targeted therapy directed against CD68+ or CD163+ cells might have deleterious effects, at least in the group of patients with a M1-predominant microenvironment.